Insider Selling: Myomo, Inc. (NYSEAMERICAN:MYO) Insider Sells 48,000 Shares of Stock

Myomo, Inc. (NYSEAMERICAN:MYO - Get Free Report) insider Micah Mitchell sold 48,000 shares of the firm's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $5.16, for a total value of $247,680.00. Following the completion of the transaction, the insider now owns 140,572 shares in the company, valued at approximately $725,351.52. This represents a 25.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Myomo Price Performance

Shares of NYSEAMERICAN MYO traded down $0.13 during mid-day trading on Tuesday, reaching $5.31. 569,341 shares of the company's stock were exchanged, compared to its average volume of 336,184. The firm has a market cap of $160.63 million, a P/E ratio of -23.09 and a beta of 1.68. Myomo, Inc. has a twelve month low of $2.51 and a twelve month high of $7.17.

Institutional Investors Weigh In On Myomo

Hedge funds have recently modified their holdings of the business. Barclays PLC acquired a new stake in shares of Myomo during the third quarter worth about $36,000. Jane Street Group LLC acquired a new stake in Myomo in the 3rd quarter valued at approximately $65,000. GSA Capital Partners LLP raised its position in Myomo by 60.8% in the 3rd quarter. GSA Capital Partners LLP now owns 103,342 shares of the company's stock valued at $414,000 after buying an additional 39,085 shares during the last quarter. Thompson Siegel & Walmsley LLC acquired a new stake in Myomo in the 4th quarter valued at approximately $1,288,000. Finally, Calamos Advisors LLC acquired a new stake in Myomo in the 4th quarter valued at approximately $189,000. Institutional investors and hedge funds own 44.99% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have weighed in on MYO shares. Ascendiant Capital Markets increased their target price on Myomo from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Monday. Alliance Global Partners reissued a "buy" rating on shares of Myomo in a research note on Tuesday, March 11th. Craig Hallum increased their target price on Myomo from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, March 11th. Finally, HC Wainwright increased their target price on Myomo from $7.50 to $9.50 and gave the company a "buy" rating in a research note on Wednesday, March 12th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $9.75.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.